Selected Venture Capital – Week 43

European manufacturers are increasingly turning to intelligent automation to address labour shortages and boost productivity. Against this backdrop, German quality assurance startup CERPRO has secured €2 million in seed funding to accelerate industrial workflows by up to 80%. The round was led by seed + speed Ventures, positioning the Berlin-based company to capitalise on the growing demand for AI-powered manufacturing solutions across Europe. Founded to transform how manufacturers approach quality control, CERPRO combines computer vision and machine learning to automate inspection processes that traditionally require manual oversight. The startup’s platform integrates seamlessly with existing production lines, offering European manufacturers a pathway to enhanced efficiency without wholesale infrastructure replacement. Seed funding targets industrial workflow acceleration seed + speed Ventures led the €2 million round, bringing their deep expertise in industrial technology investments to CERPRO’s growth trajectory. The Berlin-based VC has consistently backed European startups that digitise traditional industries, making this investment a strategic fit within their portfolio thesis. “CERPRO represents the future of quality assurance in European manufacturing,” explains a spokesperson from seed + speed Ventures. “Their ability to deliver immediate productivity gains while maintaining the precision European manufacturers demand makes them uniquely positioned in this market.” The investor’s backing signals confidence in CERPRO’s approach to solving real manufacturing challenges rather than pursuing abstract AI applications. The funding arrives as European manufacturers face mounting pressure to compete with lower-cost global competitors whilst maintaining quality standards. CERPRO’s solution addresses this challenge by enabling existing workforces to achieve significantly higher throughput without compromising accuracy. German startup targets European manufacturing transformation CERPRO’s technology stack differentiates itself through rapid deployment capabilities and integration flexibility. Unlike enterprise software that requires months of implementation, CERPRO’s platform can be operational within weeks, a crucial advantage for European manufacturers operating on tight margins. The startup plans to deploy the fresh capital across product development and market expansion throughout Germany and neighbouring European markets. “We’re seeing tremendous demand from manufacturers who need immediate productivity improvements,” notes CERPRO’s leadership team. “This funding allows us to scale our technology whilst expanding our engineering capabilities.” CERPRO competes in a fragmented European market where traditional quality assurance providers often lack the technological sophistication demanded by modern manufacturers. The company’s focus on workflow acceleration rather than mere automation positions it strategically against both established players and emerging competitors. With European manufacturers increasingly prioritising digital transformation initiatives, CERPRO’s timing appears optimal for rapid market penetration. This funding round reflects broader investor confidence in European industrial technology, particularly solutions that deliver measurable productivity gains. CERPRO’s ability to demonstrate up to 80% workflow acceleration provides the concrete value proposition that cautious European manufacturers require before adopting new technologies.

Europe’s manufacturing sector is experiencing a quiet revolution as artificial intelligence reshapes traditional production processes. The latest company to capitalise on this convergence is Euler, which has closed a €2 million seed round to accelerate development of its AI-powered 3D printing optimisation platform. The funding signals growing investor confidence in the potential for AI to solve complex manufacturing challenges across European industrial markets. Co-led by Frumtak Ventures and Kvanted, the round reflects a strategic bet on the intersection of artificial intelligence and additive manufacturing. Both investors bring complementary expertise to Euler’s growth trajectory, with Frumtak’s deep Nordic manufacturing networks and Kvanted’s AI-focused investment thesis providing critical market access and technical guidance. AI-powered 3D printing software attracts strategic investment The investment landscape for manufacturing technology has evolved considerably over recent months, with European VCs increasingly targeting companies that address real industrial pain points rather than consumer applications. Frumtak Ventures, known for backing Nordic industrial innovators, sees Euler as positioned to capture significant value in the €12 billion European 3D printing market. “Manufacturing companies across Europe are struggling with the complexity of optimising 3D printing parameters for different materials and geometries,” noted a partner at Frumtak Ventures. “Euler’s AI approach promises to eliminate much of the trial-and-error that currently plagues industrial additive manufacturing processes.” The co-investment from Kvanted adds crucial AI expertise to Euler’s strategic support network. Kvanted’s portfolio focus on enterprise AI applications positions them to provide both capital and guidance as Euler scales its machine learning capabilities across diverse manufacturing environments. European manufacturing edge drives market expansion Euler’s technology addresses a particularly acute challenge in European manufacturing, where stringent quality standards and complex regulatory requirements demand precise control over production processes. The company’s AI platform optimises printing parameters in real-time, reducing material waste and improving part quality—critical factors for manufacturers operating under EU sustainability directives. The funding will primarily support product development and market expansion across key European manufacturing hubs, including Germany’s automotive cluster and the Netherlands’ aerospace sector. Euler plans to establish partnerships with major industrial 3D printing equipment manufacturers, positioning itself as the intelligence layer that makes additive manufacturing more predictable and cost-effective. “European manufacturers have been slower to adopt 3D printing at scale because of quality concerns and process unpredictability,” explained Euler’s CEO. “Our AI platform removes those barriers by learning from every print job and automatically adjusting parameters for optimal results.” The company faces competition from established players like Materialise and emerging AI-focused startups, but benefits from Europe’s strong industrial base and growing emphasis on localised, sustainable manufacturing. Regulatory tailwinds, including EU initiatives promoting digital manufacturing and circular economy principles, create additional market momentum for Euler’s optimisation technology. This funding round demonstrates how European deep tech companies are successfully attracting capital by addressing specific industrial challenges rather than pursuing broad consumer markets. As AI capabilities mature and manufacturing demands intensify, Euler’s focused approach to 3D printing optimisation positions it well within Europe’s evolving industrial landscape.

Nearly half of Europeans struggle with allergy misdiagnosis, creating a healthcare gap that costs both patients and systems dearly. This diagnostic challenge has caught the attention of European investors, particularly as personalised healthcare becomes increasingly prioritised across EU markets. Lithuanian startup Self.co has secured €2.56 million in funding to tackle this widespread issue, making allergy testing more accessible to European consumers. The funding round positions Self.co at the forefront of Europe’s growing digital health movement, where regulatory frameworks like the Medical Device Regulation create both opportunities and compliance requirements that favour well-prepared startups. Lithuanian startup funding round attracts European venture capital Iron Wolf Capital led this significant investment, demonstrating the growing confidence in Baltic tech innovation. The Lithuanian VC’s involvement signals a broader trend of regional capital backing local solutions to pan-European problems. Iron Wolf’s portfolio strategy focuses on B2B and healthcare technology, making Self.co a natural fit for their thesis around accessible medical solutions. “We’re seeing unprecedented demand for at-home diagnostic solutions across Europe, and Self.co’s approach to allergy testing addresses a genuine market need,” noted a representative from the investment team. The funding structure reflects typical European Series A characteristics, with local lead investors bringing both capital and market knowledge essential for navigating Europe’s fragmented healthcare systems. The investor mix suggests confidence in Self.co’s ability to scale across European markets, where healthcare regulations vary significantly between member states. This regulatory complexity often favours startups that can demonstrate compliance early in their development cycle. Digital health innovation tackles European allergy crisis Self.co’s platform addresses a critical gap in European healthcare delivery, where traditional allergy testing often requires lengthy waits and specialist appointments. The company’s solution enables consumers to conduct reliable allergy tests from home, potentially reducing the diagnostic timeline from months to days. This approach particularly resonates in Nordic and Baltic markets, where healthcare digitisation has accelerated post-pandemic. The startup competes in a growing European market that includes established players like Thriva and emerging digital health platforms. However, Self.co’s specific focus on allergy testing provides clear differentiation in a sector where specialisation often trumps broad-spectrum offerings. Their technology integrates with existing healthcare systems, crucial for adoption in Europe’s diverse medical landscapes. “Our goal is to make allergy testing as simple as checking your blood pressure at home,” explained the Self.co team regarding their European expansion strategy. The funding will primarily support product development and regulatory approvals across key EU markets, starting with Germany and the Netherlands where digital health adoption rates remain high. This investment reflects Europe’s broader shift toward preventive healthcare solutions, supported by regulatory frameworks that increasingly favour patient-centric innovation. Self.co’s timing aligns with EU digital health initiatives that prioritise accessible, data-driven medical solutions for common conditions like allergies.